Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 4/20 | 0.56 |
| ▸ | MMP2 | P08253 | 3/20 | 0.56 |
| ▸ | MMP9 | P14780 | 3/20 | 0.56 |
| ▸ | MMP8 | P22894 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171628 | 0.92 | SMN1; SMN2 (0.81) | MAPK1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL3002785 | 0.88 | SMN1; SMN2 (0.75) | MAPK1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL3018224 | 0.87 | SMN1; SMN2 (0.58) | MAPK1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL3018222 | 0.87 | SMN1; SMN2 (0.58) | MAPK1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL3021492 | 0.87 | SMN1; SMN2 (0.58) | MAPK1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL3007803 | 0.86 | SMN1; SMN2 (0.72) | MAPK1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL13245266 | 0.85 | SMN1; SMN2 (0.56) | MAPK1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL3020196 | 0.85 | SMN1; SMN2 (0.56) | MAPK1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL3020195 | 0.85 | SMN1; SMN2 (0.56) | MAPK1SMN1; SMN2KMT2ATSHRLMNA | |
| SCHEMBL3019821 | 0.85 | SMN1; SMN2 (0.70) | MAPK1SMN1; SMN2KMT2ATSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171400-A1 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12227475-B2 | Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions | X-BIOTIX THERAPEUTICS, INC. | 2025-02-18 | — | — | US | disclosed |
| US-20230139502-A1 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20170349544-A1 | Ethynylbenzene Derivatives | DUKE UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-20170349544-A1 | Ethynylbenzene Derivatives | DUKE UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-9738604-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738604-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20130231323-A1 | ETHYNYLBENZENE DERIVATIVES | DUKE UNIVERSITY (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231323-A1 | ETHYNYLBENZENE DERIVATIVES | DUKE UNIVERSITY (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012031298-A2 | ETHYNYLBENZENE DERIVATIVES | DUKE UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139502-A1 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | AADAC, AZI2, CBX7 | MAPK1 3418/4885SMN1; SMN2 4038/4885KMT2A 169/4885 |
| US-12227475-B2 | Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions | AADAC, AZI2, CBX7 | MAPK1 3418/4885SMN1; SMN2 4038/4885KMT2A 169/4885 |
| US-20250171400-A1 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | AADAC, AZI2, CBX7 | MAPK1 3418/4885SMN1; SMN2 4038/4885KMT2A 169/4885 |
| US-20170349544-A1 | Ethynylbenzene Derivatives | Q6ZSR9, EPX, ZYX | MAPK1 3489/4885SMN1; SMN2 4714/4885KMT2A 2611/4885 |
| US-20130231323-A1 | ETHYNYLBENZENE DERIVATIVES | Q6ZSR9, EPX, ZYX | MAPK1 3489/4885SMN1; SMN2 4714/4885KMT2A 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.